Effectiveness of Meningococcal Serogroup C Vaccine Programmes
Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination programs, the incidence of MenC disease has declined markedly as a result of effective short-term vaccination and reduction in acquisition of MenC carriage leading to herd protection. This article, published in Vaccine, discusses the success of MCC vaccination programs in reducing the incidence of MenC, the risk of MenC incidence increasing if immunization programs are not maintained, and how regional differences in vaccination programs may influence herd protection against MenC. Further, the authors of this article assert that adolescence booster vaccinations may be required to maintain herd protection.
Author: Borrow R, Abad R, Trotter C, van der Kils FRM, Vazquez JA
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Borrow R, Abad R, Trotter C, van der Kils FRM, Vazquez JA. Effectiveness of Meningococcal Serogroup C Vaccine Programmes. Vaccine. 2013;31(41):4477-4486.
Resource types: Peer-reviewed journal
Regions: North America and Europe